Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591

Clinical Cancer Research

Volumn 14, Issue 14, 2008, Pages 4437-4445

  Vempati, Sridhar ^a,b   Reindl, Carola ^a,b   Wolf, Ulla ^a,b   Kern, Ruth ^a,b   Petropoulos, Konstantin ^a,b   Naidu, Vegi M ^a,b   Buske, Christian ^a,b   Hiddemann, Wolfgang ^a,b   Kohl, Tobias M ^a,b   Spiekermann, Karsten ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; INTERLEUKIN 3; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PHENYLALANINE; STAT5 PROTEIN; TYROSINE; FIZ1 PROTEIN, MOUSE; SIGNAL PEPTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; DNA SEQUENCE; FLOW CYTOMETRY; GENE ACTIVATION; GENE CONSTRUCT; GENE DUPLICATION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFORMATION; IN VITRO STUDY; LIGAND BINDING; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; CELL LINE; CELL TRANSFORMATION; CHEMISTRY; ENZYME ACTIVATION; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; PHOSPHORYLATION; PHYSIOLOGY; POINT MUTATION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PHOSPHORYLATION; POINT MUTATION; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE;

EID: 51649125545     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1873     Document Type: Article

References (48)

1. Rosnet O, Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit Rev Oncog 1993;4:595-613.
2. Lyman SD, Jacobsen SE. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998;91:1101-34.
3. Srinivasa SP, Doshi PD. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line. Leukemia 2002; 16:244-53.
4. Zhang S, Broxmeyer HE. Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase. Biochem Biophys Res Commun 2000;277:195-9.
5. Zhang S, Fukuda S, Lee Y, et al. Essential role of signal transducer and activator of transcription (Stat) 5a but not Stat5b for Flt3-dependent signaling. J Exp Med 2000;192:719-28.
6. Zhang S, Mantel C, Broxmeyer HE. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J Leukoc Biol 1999;65:372-80.
7. + lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell 2005;121295-306
8. Christensen JL, Weissman IL. Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad Sci U S A 2001;98:14541-6.
9. Sitnicka E, Buza-Vidas N, Larsson S, Nygren JM, Liuba K, Jacobsen SE. Human CD34 hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct fIt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood 2003;102:881-6.
10. Schnittger S, Schoch C, Dugas M, et al Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics. FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66.
11. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3- activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 2002;99:4326-35
12. +/CD33 precursors predicts poor outcome in acute myeloid leukemia. Blood 2006;108:2764-9.
13. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98: 1752-9.
14. 835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001;113:983-8.
15. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97: 2434-9.
16. Schessl C, Rawat VP, Cusan M, et al. The AMLI-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 2005; 115:2159-68.
17. Kelly LM, Kutok JL, Williams IR, et al. PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A 2002;99:8283-8.
18. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105: 54-60.
19. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108:3262-70.
20. Bagrintseva K, Schwab R, Kohl TM, et al. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood 2004;103:2266-75.
21. Kohl TM, Schnittger S, Ellwart JW. Hiddemann W, Spiekermann K. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 2005;105: 3319-21.
22. Spiekermann K, Dirschinger RJ, Schwab R, et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 2003;101:1494-504.
23. Greif PA, Tizazu B, Krause A, Kremmer E, Bohlander SK. The leukemogenic CALM/AF10 fusion protein alters the subcellular localization of the lymphoid regulator Ikaros. Oncogene 2007;27:2886-96.
24. Roskoski R, Jr. Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 2005;338:1307-15.
25. Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res 2003;9:2140-50.
26. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000;19:624-31.
27. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000;96:3907-14.
28. Kyoi H, Ohno R. Vedla R, Saito H, Naoe T. Mechanism of constitutive action of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002;21:2555-63.
29. Rocnik JL, Okabe R, Yu JC, et al. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood 2006;108:1339-45.
30. Heiss E, Masson K, Sundberg C, et al. Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood 2006;108: 1542-50.
31. Griffith J, Black J, Faerman C, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 2004;13:169-78.
32. Ma Y Cunningham ME, Wang X, Ghosh I, Regan L, Longley BJ. Inhibition of spontaneous receptor phosphorylation by residues in a putative a-helix in the KIT intracellular juxtamembrane region. J Biol Chem 1999; 274:13399-402.
33. Price DJ, Rivnay B, Avraham H. CHK down-regulates SCF/KL-activated Lyn kinase activity in Mo7e megakaryocytic cells. Biochem Biophys Res Commun 1999;259:611-6.
34. Gelderloos JA, Rosenkranz S, Bazenet C, Kazlauskas A. A role for Src in signal relay by the platelet-derived growth factor α receptor. J Biol Chem 1998;273: 5908-15.
35. Hooshmand-Rad R. Yokote K, Heldin CH, Claesson-Welsh L. PDGFα-receptor mediated cellular responses are not dependent on Src family kinases in endothelial cells. J Cell Sci 1998;111:607-14.
36. Valgeirsdottir S, Paukku K, Silvenoinnon O, Heldin CH, Claesson-Welch L. Activation of STAT5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation cells in PDGF beta receptor juxtamembrane and kinase insert domains Oncogene 1998;16:605-15.
37. Baxter RM, Secrist JP, Vaillancourt RR, Kazlauskas A. Full activation of the platelet-derived growth factor β-receptor kinase involves multiple events. J Biol Chem 1998;273:17050-5.
38. Kimura Y Jones N, Kluppel M, et al. Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages. Proc Natl Acad Sci U S A 2004;101: 6015-20.
39. Mori S, Ronnstrand L. Yokote K, et al. Identification of two juxtamembrane autophosphorylation sites in the PDGFβ-receptor; involvement in the interaction with Src family tyrosine kinases. EMBO J 1993;12: 2257-64.
40. Rohde CM, Schrum J, Lee AW. A juxtamembrane tyrosine in the colony stimulating factor-1 receptor regulates ligand-induced Src association, receptor kinase function, and down-regulation. J Biol Chem 2004;279:43448-61.
41. Vaillancourt RR, Heasley LE, Zamarripa J, et al. Mitogen-activated protein kinase activation is insufficient for growth factor receptor-mediated PD2 cell differentiation. Mol Cell Biol 1995;15:3644-53.
42. Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003;101:2940-54.
43. Gouilleux-Gruart V, Gouilleux F, Desaint C, et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 1996;87:1692-7.
44. Hayakawa F, Towatari M, lida H, et al. Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukemia. Br J Haematol 1998;101:521-8.
45. Xia Z, Baer MR, Block AW, Baumann H, Wetzler M. Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res 1998;58:3173-80.
46. Calo V, Migliavacca M, Bazan V, et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 2003;197:157-68.
47. Vander Heiden MG, Chandel NS, Williamson EK, Schumacker PT, Thompson CB. Bcl-x L regulates the membrane potential and volume homeostasis of mitochondria. Cell 1997;91:627-37.
48. Okutani Y Kitanaka A, Tanaka T, et al. Src directly tyrosine- phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene 2001;20:6643-50.